BRPI0716749B8 - compostos pirido (2,3-d) pirimidinona, seu uso como inibidores pi3 e composição farmacêutica que os compreende - Google Patents
compostos pirido (2,3-d) pirimidinona, seu uso como inibidores pi3 e composição farmacêutica que os compreendeInfo
- Publication number
- BRPI0716749B8 BRPI0716749B8 BRPI0716749A BRPI0716749A BRPI0716749B8 BR PI0716749 B8 BRPI0716749 B8 BR PI0716749B8 BR PI0716749 A BRPI0716749 A BR PI0716749A BR PI0716749 A BRPI0716749 A BR PI0716749A BR PI0716749 B8 BRPI0716749 B8 BR PI0716749B8
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitors
- pyrido
- pharmaceutical composition
- pyrimidinone compounds
- compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- MHHOMHMNIRXARC-UHFFFAOYSA-N 1h-pyrido[2,3-d]pyrimidin-2-one Chemical class C1=CN=C2NC(=O)N=CC2=C1 MHHOMHMNIRXARC-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 abstract 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 abstract 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 pyrimidinone compound Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84506506P | 2006-09-15 | 2006-09-15 | |
| US60/845,065 | 2006-09-15 | ||
| US94785207P | 2007-07-03 | 2007-07-03 | |
| US60/947,852 | 2007-07-03 | ||
| US95262807P | 2007-07-30 | 2007-07-30 | |
| US60/952,628 | 2007-07-30 | ||
| PCT/IB2007/002578 WO2008032162A1 (en) | 2006-09-15 | 2007-09-03 | Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0716749A2 BRPI0716749A2 (pt) | 2014-02-18 |
| BRPI0716749B1 BRPI0716749B1 (pt) | 2020-10-06 |
| BRPI0716749B8 true BRPI0716749B8 (pt) | 2021-05-25 |
Family
ID=38859750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0716749A BRPI0716749B8 (pt) | 2006-09-15 | 2007-09-03 | compostos pirido (2,3-d) pirimidinona, seu uso como inibidores pi3 e composição farmacêutica que os compreende |
Country Status (41)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY146420A (en) | 2006-09-15 | 2012-08-15 | Pfizer Prod Inc | Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors |
| DK2139484T3 (da) * | 2007-04-10 | 2013-10-21 | Exelixis Inc | Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa |
| AU2008239596B2 (en) * | 2007-04-11 | 2013-08-15 | Exelixis, Inc. | Pyrido [2,3-D] pyrimidin-7-one compounds as inhibitors of PI3K-alpha for the treatment of cancer |
| CA2729914A1 (en) * | 2008-07-11 | 2010-01-14 | Novartis Ag | Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway |
| WO2010022126A1 (en) | 2008-08-20 | 2010-02-25 | Schering Corporation | Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| JP5731976B2 (ja) | 2008-08-20 | 2015-06-10 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 置換ピリジン誘導体および置換ピリミジン誘導体ならびにそれらのウイルス感染の治療における使用 |
| CA2734487A1 (en) | 2008-08-20 | 2010-02-25 | Southern Research Institute | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| CA2734489C (en) * | 2008-08-20 | 2016-11-08 | Southern Research Institute | Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| TW201018685A (en) * | 2008-09-30 | 2010-05-16 | Exelixis Inc | Pyridopyrimidinone inhibitors of PI3Kα and mTOR |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| JP5775171B2 (ja) | 2010-12-16 | 2015-09-09 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 三環系ｐｉ３ｋ阻害剤化合物及びその使用方法 |
| US8664230B2 (en) * | 2011-03-17 | 2014-03-04 | The Asan Foundation | Pyridopyrimidine derivatives and use thereof |
| TW201306842A (zh) * | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法 |
| EP2750675A1 (en) | 2011-08-31 | 2014-07-09 | Novartis AG | Synergistic combinations of pi3k- and mek-inhibitors |
| CN104829609B (zh) * | 2014-02-11 | 2016-08-03 | 北大方正集团有限公司 | 取代的吡啶并嘧啶化合物及其制备方法和应用 |
| WO2016015597A1 (en) | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Compounds as cdk small-molecule inhibitors and uses thereof |
| CN105330699B (zh) * | 2014-08-13 | 2018-12-04 | 山东汇睿迪生物技术有限公司 | 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用 |
| US10617670B2 (en) | 2014-10-10 | 2020-04-14 | Pfizer Inc. | Synergistic auristatin combinations |
| EP3636283A1 (en) | 2015-06-04 | 2020-04-15 | Pfizer Inc | Solid dosage forms of palbociclib |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| EP4086250B1 (en) | 2016-07-06 | 2024-12-11 | The Regents Of The University Of Michigan | Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same |
| CU24522B1 (es) | 2016-08-15 | 2021-06-08 | Pfizer | PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONAS 6-FLUOROALQUIL-2-(ALQUILSULFONILPIPERIDIN-4-IL)AMINO SUSTITUIDAS |
| US11241500B2 (en) * | 2016-12-14 | 2022-02-08 | Tarveda Therapeutics, Inc. | HSP90-targeting conjugates and formulations thereof |
| WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
| CN117843659A (zh) | 2018-06-15 | 2024-04-09 | 詹森药业有限公司 | 雷帕霉素类似物和其用途 |
| AU2019413683B2 (en) * | 2018-12-28 | 2025-05-22 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| US20220220103A1 (en) * | 2018-12-28 | 2022-07-14 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| US11583538B2 (en) | 2019-04-08 | 2023-02-21 | Venenum Biodesign, LLC | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors |
| US11819476B2 (en) | 2019-12-05 | 2023-11-21 | Janssen Pharmaceutica Nv | Rapamycin analogs and uses thereof |
| CN114901664B (zh) * | 2020-01-10 | 2024-07-02 | 南京再明医药有限公司 | 吡啶酮化合物及应用 |
| WO2022075974A1 (en) * | 2020-10-06 | 2022-04-14 | Venenum Biodesign, LLC | Cyclic trex1 inhibitors |
| WO2022109001A1 (en) | 2020-11-18 | 2022-05-27 | Deciphera Pharmaceuticals, Llc | Gcn2 and perk kinase inhibitors and methods of use thereof |
| CN118678960A (zh) * | 2021-11-18 | 2024-09-20 | 安可诺瓦治疗公司 | 用于治疗癌症的方法和组合物 |
| AU2024286830A1 (en) | 2023-06-08 | 2025-12-04 | Nimbus Wadjet, Inc. | Wrn inhibitors |
| WO2025137599A1 (en) * | 2023-12-21 | 2025-06-26 | Nimbus Wadjet, Inc. | Wrn inhibitors |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5264437A (en) * | 1992-03-20 | 1993-11-23 | Syntex (U.S.A.) Inc. | Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones |
| PT790997E (pt) | 1994-11-14 | 2000-06-30 | Warner Lambert Co | 6-aril pirido¬2,3-d|pirimidinas e naftiridinas para inibir a proliferacao celular mediada pela quinase da tirosina proteica |
| CN1177960A (zh) * | 1995-03-10 | 1998-04-01 | 圣诺菲药品有限公司 | 6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法 |
| IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| US5925761A (en) | 1997-02-04 | 1999-07-20 | Sepracor Inc. | Synthesis of terfenadine and derivatives |
| US6498163B1 (en) | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| KR20000070751A (ko) | 1997-02-05 | 2000-11-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘 |
| GB9904932D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy |
| CA2394525A1 (en) | 2000-01-27 | 2001-08-02 | Warner-Lambert Company | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease |
| JP2003528101A (ja) | 2000-03-06 | 2003-09-24 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | ５−アルキルピリド［２，３−ｄ］ピリミジンチロシンキナーゼ阻害剤 |
| EP1277738B1 (en) | 2000-04-27 | 2011-03-30 | Astellas Pharma Inc. | Condensed heteroaryl derivatives |
| AU2002233706C1 (en) | 2001-02-26 | 2005-12-22 | Tanabe Seiyaku Co., Ltd. | Pyridopyrimidine or naphthyridine derivative |
| US7019002B2 (en) * | 2001-12-11 | 2006-03-28 | Pharmacia & Upjohn, S.P.A. | Pyridopyrimidinones derivatives as telomerase inhibitors |
| KR20060111716A (ko) | 2002-01-22 | 2006-10-27 | 워너-램버트 캄파니 엘엘씨 | 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온 |
| JP2003321472A (ja) | 2002-02-26 | 2003-11-11 | Takeda Chem Ind Ltd | Ｇｒｋ阻害剤 |
| RU2004133811A (ru) | 2002-04-19 | 2005-04-20 | Смитклайн Бичам Корпорейшн (US) | Новые соединения |
| MXPA04010983A (es) | 2002-05-06 | 2005-02-14 | Genelabs Tech Inc | Derivados de nucleosidos para tratar infecciones por el virus de la hepatitis c. |
| JP2004083587A (ja) | 2002-08-06 | 2004-03-18 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| US7098332B2 (en) * | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| JP2004203751A (ja) | 2002-12-24 | 2004-07-22 | Pfizer Inc | 置換６，６−ヘテロ二環式誘導体 |
| US20050009849A1 (en) | 2003-01-03 | 2005-01-13 | Veach Darren R. | Pyridopyrimidine kinase inhibitors |
| WO2004089930A1 (en) | 2003-04-02 | 2004-10-21 | Imclone Systems Incorporated | 4-fluoroquinolone derivatives and their use as kinase inhibitors |
| JP2007504283A (ja) | 2003-05-20 | 2007-03-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | β−アミロイド斑に作用物質を結合させる方法 |
| RU2317296C2 (ru) | 2003-07-11 | 2008-02-20 | Уорнер-Ламберт Компани Ллс | Изетионатная соль селективного ингибитора cdk4 |
| EP1660087A2 (en) | 2003-07-22 | 2006-05-31 | Janssen Pharmaceutica N.V. | Quinolinone derivatives as inhibitors of c-fms kinase |
| US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| JP4989233B2 (ja) | 2004-02-14 | 2012-08-01 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| EP1718645A1 (en) | 2004-02-18 | 2006-11-08 | Warner-Lambert Company LLC | 2-(pyridin-3-ylamino)-pyrido 2,3-d pyrimidin-7-ones |
| EP1740184A1 (en) | 2004-03-30 | 2007-01-10 | Pfizer Products Incorporated | Combinations of signal transduction inhibitors |
| WO2005105097A2 (en) | 2004-04-28 | 2005-11-10 | Gpc Biotech Ag | Pyridopyrimidines for treating inflammatory and other diseases |
| US20080255162A1 (en) * | 2004-05-04 | 2008-10-16 | Warner-Lambert Company Llc | Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents |
| WO2005117980A1 (en) | 2004-06-04 | 2005-12-15 | Pfizer Products Inc. | Method for treating abnormal cell growth |
| CA2575804A1 (en) | 2004-08-26 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Pteridinones used as plk (polo like kinase) inhibitors |
| US7608594B2 (en) | 2004-11-03 | 2009-10-27 | University Of Kansas | Novobiocin analogues as anticancer agents |
| WO2006065703A1 (en) | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| US20060142312A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
| HRP20130902T1 (hr) * | 2005-10-07 | 2013-11-08 | Exelixis Inc. | PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa |
| US8247408B2 (en) * | 2005-10-07 | 2012-08-21 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer |
| EP1872922A1 (en) * | 2006-06-27 | 2008-01-02 | Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO | Method and apparatus for manufacturing a polymeric article |
| CA2658725A1 (en) | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
| MY146420A (en) | 2006-09-15 | 2012-08-15 | Pfizer Prod Inc | Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors |
| MX2009009786A (es) * | 2007-03-14 | 2009-09-24 | Exelixis Inc | Inhibidores de la via de hedgehog. |
| AU2008239596B2 (en) | 2007-04-11 | 2013-08-15 | Exelixis, Inc. | Pyrido [2,3-D] pyrimidin-7-one compounds as inhibitors of PI3K-alpha for the treatment of cancer |
| TW201018685A (en) | 2008-09-30 | 2010-05-16 | Exelixis Inc | Pyridopyrimidinone inhibitors of PI3Kα and mTOR |
| JP2013525308A (ja) * | 2010-04-16 | 2013-06-20 | キュリス，インコーポレイテッド | Ｋ−ｒａｓ変異を有する癌の治療 |
-
2007
- 2007-09-03 MY MYPI20091013A patent/MY146420A/en unknown
- 2007-09-03 PT PT07804890T patent/PT2074122E/pt unknown
- 2007-09-03 JP JP2009527908A patent/JP4718637B2/ja active Active
- 2007-09-03 CN CN2007800342100A patent/CN101573358B/zh not_active Expired - Fee Related
- 2007-09-03 EP EP07804890.7A patent/EP2074122B9/en active Active
- 2007-09-03 RS RSP-2009/0104A patent/RS20090104A/sr unknown
- 2007-09-03 AP AP2009004790A patent/AP2710A/xx active
- 2007-09-03 RS RS20110379A patent/RS51927B/sr unknown
- 2007-09-03 AU AU2007297212A patent/AU2007297212B8/en not_active Ceased
- 2007-09-03 NZ NZ575167A patent/NZ575167A/en not_active IP Right Cessation
- 2007-09-03 DK DK07804890.7T patent/DK2074122T5/da active
- 2007-09-03 CA CA2663401A patent/CA2663401C/en not_active Expired - Fee Related
- 2007-09-03 KR KR1020097005342A patent/KR101099926B1/ko not_active Expired - Fee Related
- 2007-09-03 ME MEP-80/09A patent/MEP8009A/xx unknown
- 2007-09-03 HR HRP20110621TT patent/HRP20110621T2/hr unknown
- 2007-09-03 AT AT07804890T patent/ATE514695T1/de active
- 2007-09-03 ES ES07804890T patent/ES2366489T3/es active Active
- 2007-09-03 BR BRPI0716749A patent/BRPI0716749B8/pt not_active IP Right Cessation
- 2007-09-03 EA EA200970207A patent/EA016388B1/ru not_active IP Right Cessation
- 2007-09-03 MX MX2009002927A patent/MX2009002927A/es active IP Right Grant
- 2007-09-03 SI SI200730715T patent/SI2074122T1/sl unknown
- 2007-09-03 GE GEAP200711157A patent/GEP20115306B/en unknown
- 2007-09-03 WO PCT/IB2007/002578 patent/WO2008032162A1/en not_active Ceased
- 2007-09-03 PL PL07804890T patent/PL2074122T3/pl unknown
- 2007-09-12 UY UY30588A patent/UY30588A1/es not_active Application Discontinuation
- 2007-09-13 AR ARP070104059A patent/AR062785A1/es not_active Application Discontinuation
- 2007-09-13 PE PE2007001238A patent/PE20080670A1/es not_active Application Discontinuation
- 2007-09-13 GT GT200700077A patent/GT200700077A/es unknown
- 2007-09-13 US US11/854,999 patent/US7696213B2/en not_active Expired - Fee Related
- 2007-09-14 TW TW096134605A patent/TWI334353B/zh not_active IP Right Cessation
- 2007-09-14 CL CL200702682A patent/CL2007002682A1/es unknown
- 2007-09-17 HN HN2007000267A patent/HN2007000267A/es unknown
-
2009
- 2009-02-25 IL IL197243A patent/IL197243A/en active IP Right Grant
- 2009-03-02 ZA ZA200901477A patent/ZA200901477B/xx unknown
- 2009-03-11 DO DO2009000039A patent/DOP2009000039A/es unknown
- 2009-03-13 TN TN2009000085A patent/TN2009000085A1/fr unknown
- 2009-03-13 CU CU20090040A patent/CU23783B7/es not_active IP Right Cessation
- 2009-03-13 MA MA31707A patent/MA30709B1/fr unknown
- 2009-03-13 NI NI200900032A patent/NI200900032A/es unknown
- 2009-03-13 CR CR10662A patent/CR10662A/es unknown
- 2009-03-18 NO NO20091141A patent/NO342357B1/no not_active IP Right Cessation
-
2010
- 2010-02-09 US US12/702,937 patent/US8273755B2/en not_active Expired - Fee Related
-
2011
- 2011-07-20 CY CY20111100714T patent/CY1111911T1/el unknown
-
2012
- 2012-08-16 US US13/587,825 patent/US8633204B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0716749B8 (pt) | compostos pirido (2,3-d) pirimidinona, seu uso como inibidores pi3 e composição farmacêutica que os compreende | |
| CO6321276A2 (es) | Derivados de tiazol usados como inhibidores de pi3- cinasa | |
| ECSP12012334A (es) | Morfolinopirimidinas y su uso en terapia | |
| CR10356A (es) | Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3 | |
| UY32379A (es) | Derivados de n-heteroarilo sulfonammida sustituidos, sales, solvatos o tautómero farmacéuticamente aceptables, procesos de preparación, intermedios, composicones conteniéndolos y aplicaciones. | |
| BR112013021638A2 (pt) | "compostos inibidores de trk, seu uso e composições que os compreendem" | |
| DOP2011000361A (es) | Nuevos derivados de pirimidina y sus usos en el tratamiento del cancer y otras enfermedades | |
| DOP2014000303A (es) | 7H-PIRROLO[2,3-d] PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2 | |
| BRPI0910388A2 (pt) | agentes terapêutico antivirais. | |
| BRPI1009333B8 (pt) | compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica | |
| UY31260A1 (es) | Compuestos de pirazol, composiciones conteniendolos y aplicaciones. | |
| CR11793A (es) | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas | |
| ECSP099565A (es) | Compuesto de 2-amino pirimidina | |
| UY32420A (es) | Derivados de 6-(6-sustituido-triazolopiridazina-sulfanil)benzotiazoles y bencimidazoles : preparacion, aplicacion como medicamentos y utilizacion como inhibidores de met | |
| BR112014031969A2 (pt) | derivados de pirimidinona como agentes antimaláricos | |
| DOP2010000155A (es) | Derivados de pirazol como inhibidores de 5-lo | |
| UY31161A1 (es) | Usos de derivados de cinolina en el tratamiento de la esquizofrenia | |
| CL2023003791A1 (es) | Compuestos pirimidínicos para usar como inhibidores de map4k1 | |
| UY32412A (es) | DERIVADOS DE 4-AMINO-7,8-DIHIDROPIRIMIDO [4,3-d] PIRIMIDIN-5 (6H)-ONA | |
| UY31289A1 (es) | Nuevos derivados de la quinoliniloxipiperidina y pirrolidina, su preparacion, composiciones farmaceuticas que los contiene y sus usos en el tratamieno de enfermedades | |
| UA95113C2 (en) | Pyrido (2,3-d) pyrimidin0ne compounds and their use as pi3 inhibitors | |
| TH151329A (th) | ไพริมิดิโนนเป็นสารยับยั้ง pi3k | |
| CU23957B1 (es) | Derivados de tiazolidin-2,4-diona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/09/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 15A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2686 DE 28-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |